Introduction
============

Clinical trials are important to improve and advance medical science and public health. A reliable partnership between patients, physicians, ECs, regulatory authorities, and sponsors is a prerequisite. For the conduct of clinical trials, the ECs have been proven to be an important element for assuring the rights, well-being, safety, and data protection of clinical trial subjects.

Clinical studies are very often conducted on a global scale. Taking competitive recruitment into account, high ethical standards combined with a timely review and approval process is a key element while setting up clinical studies in Germany. In order to support the tasks and responsibilities of ECs, seamless cooperation between ECs and sponsors is mandatory.

In 2008 a survey was performed by vfa to analyze the status of interactions between ECs and sponsors for the first time. Data showed that a major heterogeneity among ECs existed with respect to individual requirements and evaluations, in particular concerning patient information and consent documents as well as site and investigator qualifications. However, mutually agreed solutions were found in most cases of dissent between applicants and ECs by means of a constructive dialogue \[[@R1]\].

In order to follow-up on these findings and to verify the process of EC submission, evaluation, and EC-sponsor-interactions again, a second survey using the same questionnaire was performed 4 years later in 2012. Importantly, in these 4 years there were no legal changes in the clinical study regulatory environment. The legal framework is also described by Russ et al. in 2009 \[[@R1]\].

The conclusions drawn may provide evidence for both sponsors and ECs on how to further improve the quality of study applications and the harmonization of the EC review process, respectively.

Methods
=======

The present survey among all 44 member companies of the vfa was conducted from July to September 2012, based on reasoned opinions issued by the respective EC in charge of the coordinating principle investigator (coordinating EC) from January to December 2011.

The same questionnaire as for the first survey was used again ([Attachment 1](#SD1){ref-type="supplementary-material"}, [Attachment 2](#SD2){ref-type="supplementary-material"}). Among others, it captures the type and number of formal and content-related objections in the decisions of coordinating ECs after first application for a clinical trial pursuant to GCP-V § 7 (1--3) \[[@R2]\]. In detail, 10 questions asked for the number of initial applications, i.e. studies, the clinical trial phase, therapeutic indication, name of the respective coordinating EC, the number of formal and content-related objections per study application along with a brief description of the issue, the subjective evaluation and the applicant's response to the objections, and whether or not the EC objection was challenged. The responding companies also classified the objections into 6 pre-specified evaluation categories. These were: Formal deficiencies pursuant to GCP-V § 8 (1) as well as 5 categories of content-related objections regarding patient information and consent document, trial protocol content, investigator and site qualifications, other application documents pursuant to GCP-V § 7 (2) and (3), and requests, remarks and recommendations not directly related to the application documents submitted pursuant to GCP-V § 7 (2) and (3), called "miscellaneous" here (see Figure 1 [(Fig. 1)](#F1){ref-type="fig"}). As a slight variation to the first questionnaire, the second survey asked additionally, whether the sponsor company itself or a Clinical Research Organization (CRO) was acting as applicant.

Overall, the two surveys are based on similar data sets and were used for descriptive comparison. No formal statistics were pre-specified or applied.

In the following section, the data of the current investigation are presented in comparison to the first survey. The results of 2007 \[[@R1]\], are given in parentheses.

Results
=======

Of the 44 (44) companies organized in the vfa and included in the survey, 24 (22) companies were represented on the vfa Clinical Research/Quality Assurance Subcommittee. Eighteen (21) out of these 24 (22) companies took part in the survey. A total of 251 (288) applications for phase I--IV studies submitted by these 18 (21) companies to 43 (40) ECs in 2011 were evaluated. These account for about 21% of all 1,214 applications for authorization of commercial and non-commercial phase I--IV clinical trials submitted to the regulatory authorities (BfArM and PEI) in 2011 \[[@R3]\], \[[@R4]\].

A breakdown by clinical trial phase and therapeutic indication for the 251 evaluated applications is given in Table 1 [(Tab. 1)](#T1){ref-type="fig"} and Table 2 [(Tab. 2)](#T2){ref-type="fig"}. No statistically significant difference (95% CI) was noted with respect to the category of the clinical trial phase (Table 1 [(Tab. 1)](#T1){ref-type="fig"}) when comparing 2011 to 2007. A statistically significant increase in oncology trials from 17.3% (21.9%, 13.5%) in 2007 to 27.1% (32.6%, 22.1%) in 2011 was reported whereas the proportion of studies in all other therapeutic indications changed only slightly (Table 2 [(Tab. 2)](#T2){ref-type="fig"}).

Out of the study applications analyzed, 88% were submitted by the sponsor or the legal representative of the sponsor in the EU. In 12% of cases CROs authorized by the sponsors made the application. From the 18 members of the vfa who participated in the survey 2012 (in 2008 the survey didn't ask for the type of applicant), 9 companies performed the EC applications exclusively by themselves, 7 companies either performed the applications by themselves or delegated this task to CROs and only 2 companies had the EC submissions solely conducted by CROs.

Frequency of formal and content-related objections in relation to total objections
----------------------------------------------------------------------------------

Objections reported in reference to the patient information and consent document accounted for 57% (53%) of the total 1,574 (1,299) EC objections, followed by 19% (19%) objections related to the submitted trial protocol. Another 8% (7%) of total objections were due to formal deficiencies in other application documents according to GCP-V § 7 (2, 3) and 6% (7%) were due to formal deficiencies pursuant to GCP-V § 8 (1). Only 3% (5%) of total objections were in relation to specific documents on the site or investigators. Objections summarized under the categories of requests, remarks and recommendations not directly related to the application documents submitted pursuant to § 7 (2) and (3) (called "miscellaneous" here) contributed 8% (9%) (cf. Figure 1 [(Fig. 1)](#F1){ref-type="fig"}).

Very similar to 2007, 26% (24%) of objections to the applications were reported by the vfa-members as having a lack of legal basis or it was claimed that the relevant information was already provided as part of the submission package, but had not been taken into consideration by the ECs. In such cases, the applicants made reference to the submitted documents or provided detailed explanations for not acting on the objections. The proportion of not mutually agreeable objections was highest in the categories of "Trial protocol content" 59% (44%), "Other documents pursuant to GCP-V § 7 (2) and (3)" 41% (33%), and "Miscellaneous" 46% (46%). Applicants acted on the majority of objections in the categories "investigator and site qualifications" and "patient information and consent document", with response rates of 83% (87%) and 89% (85%), respectively.

Frequency of formal and content-related objections in relation to study applications
------------------------------------------------------------------------------------

An analysis of study applications in terms of formal and content-related objections (cf. Figure 2 [(Fig. 2)](#F2){ref-type="fig"}) shows that 85.7% (78.5%) of all study applications received at least one objection related to the submitted patient information and consent document. An amount of 56.6% (45.1%) of all study applications received at least one objection in terms of trial protocol content. The number of applications with objections to documents pursuant to § 7 (2) and (3) GCP-V increased from 22.5% in 2007 to 34.3% in 2011 whereas the number of applications with specific objections to investigator and sites qualifications decreased by 6.3% from 18.7% in 2007 to 12.4% in 2011. The proportion of incomplete applications with formal objections was 16.7% (16%) in this survey. Sixteen (24) out of the 251 (288) study applications (total 6.4% (8.3%) had neither formal nor content-related objections, while 4 (3) study applications were rejected on grounds of study design. The 10-day time limit for formal EC review was not missed (only 1 application in 2007). The ECs exceeded the 60-day processing time for content-based review for a total of 9 (8) applications (3.6% (2.8%)). No statistically significant difference (95% CI) in the frequency of objections in phase I study applications between 2007 and 2011 was observed. For phase II--IV study applications, only a statistically significant increase in objections concerning application documents pursuant to § 7 (2) and (3) GCP-V from 22% (95% CI: 27%, 17%) in 2007 to 37% in 2011 (43%, 31%) was detected.

Breakdown of study applications and breakdown of frequency of formal and content-related objections in relation to the ECs involved in the survey
-------------------------------------------------------------------------------------------------------------------------------------------------

A percentage of 48.2% (54.9%) of the 251 (288) study applications were submitted to 14 (14) ECs of state chambers of physicians and federal states. 51.8% (45.1%) were submitted to 29 (26) ECs of university hospitals. Only 8 (18.6%) of the total of 43 ECs involved in this survey each reviewed at least 10 applications, amounting to a total of 123 applications and hence accounting for almost half (49%) of all study applications. In 2007 10 (25%) of the total of 40 ECs were accounting for roughly half (53.8%) of all study applications. Figure 3 [(Fig. 3)](#F3){ref-type="fig"} shows the number of study applications per EC.

Stratification of all ECs into two groups according to the number of applications reviewed by each (cf. Table 3 [(Tab. 3)](#T3){ref-type="fig"}) shows that 60.5% (57.7%) of ECs reviewed only up to 5 study applications each, i.e. 25.1% (27.1%) of all study applications. These ECs on average raised less objections per application than the ECs in the group that each reviewed more than 5 applications. In 2007 the situation was contrary meaning all ECs especially those reviewing more than 5 applications were more homogeneous in their assessments of study applications. This EC group represents 39.5% (42.5%) of the 43 (40) ECs involved and reviewed 74.9% (72.9%) of the total 251 (288) study applications.

The data also suggest a slightly different pattern of objections between ECs of state chambers of physicians and federal states on one hand and university hospitals on the other hand. About 60% of objections from ECs at university hospitals were in reference to the patient information and consent document compared to 53% from ECs of state chambers of physicians and federal states. Another 8% versus 4% of objections are related to formal deficiencies pursuant to GCP-V § 8 (1). Whereas 22% of objections from ECs at state chambers of physicians and federal states fell under the category trial protocol content opposed to 16% in that category from ECs at university hospitals.

The pattern of objections by each individual EC is shown in Figure 4 [(Fig. 4)](#F4){ref-type="fig"}. The frequency distribution of the objections matched to the respective review categories (trial protocol content, investigator and site qualifications etc.) shows a very heterogeneous picture among the ECs.

Type of formal and content-related objections
---------------------------------------------

Pursuant to GCP-V § 8, content-related review by an EC begins only after complete submission. If there are formal deficiencies, i.e. missing or incomplete documents pursuant to GCP-V § 7 (2) and (3), the applicant has 14 calendar days in which to address those deficiencies. The 30-day (for mono-center clinical trials) and 60-day time limit (for multi-center clinical trials) for content-related review of the study application begins after complete submission. Incomplete applications defer the review phase and prolong the overall procedure.

The formal and content-related objections are listed in descending order of frequency.

Formal objections
-----------------

These are the most common formal deficiencies pursuant to GCP-V § 8 (1):

Missing or incomplete information on the qualifications of investigators/and or site suitability, e.g. missing proofs of qualifications (CVs, GCP certificate), inadequate description of patient recruitment process, and missing information about concurrent studies (GCP-V § 7 (3) 6. and 8.)Missing statement on information concerning possible financial and other interests of investigators in connection with the investigational medicinal products (GCP-V § 7 (3) 7.)Missing consent of hospital director or head of department to study conductMissing CRFMissing sponsor confirmation that every investigator was informed of pharmacology/toxicology results by a scientist responsible for pharmacology/toxicology testing and the risks likely associated with the clinical trial (Drug Law § 40 (1) (7))

Content-related objections
--------------------------

In keeping with the outcome of the survey, by far the most common content-related objections concern the submitted **patient information and consent documents**. Typical objections:

Present patient information in language accessible to laypersons and explain jargonPresent patient information with contact details and address of investigator/site, e.g. in the form of letterheadPresent more clearly or add information on risks, adverse effects or side effects stating the percent frequency, based on the investigator brochure or package leafletProvide more specific details about the pseudonymisation process in the data protection sectionPoint out in the insurance cover section that the insurance terms are to be handed out to patients, and state clearly what the patient should do in the event of a possible injury/claim or emergencyClearly and precisely state the allowed birth control methodsState that the primary care physician is to be informed of the patient's study participation with the patient's consent

Other content-related objections concerned the submitted **trial protocol**. The respondent companies cited the following items as being the most common requests in connection with trial protocol content:

More precise description of existing inclusion/exclusion and/or additional inclusion/exclusion criteriaSpecific discontinuation criteria for the individual subject and for the entire clinical trialJustify the study design (placebo arm in particular), the scientific rationale, the sample size and/or the primary endpoint(s)

Objections relating to **investigator qualifications and site suitability** were reported as follows:

Investigator qualifications:Incomplete CVs (e.g. missing information about number of studies previously conducted)Inadequate proof of existing GCP knowledge; mention of the need for a Drug Law/GCP-V courseInformation missing on other medical staff involved in the study.

Site suitability:Requests for hospital director or head of department's consent to study conduct.Missing information on concurrent studies and any measures to ensure recruitment.

Typical objections concerning **application documents pursuant to GCP-V § 7 (2) and (3***)* were:

Requests to modify terms and conditions of the patient insurance or to provide study-specific insurance certificate despite the submission of appropriate patient insurance certificate pursuant to the Drug Law § 40 (§ 7 (3) 13.))Provide clarification regarding remuneration and publication in the sponsor-site agreementAdjust wording of advertisement for patient recruitmentAdjust wording of patient emergency card

A large number of requests, remarks and recommendations not directly related to the application documents to be submitted pursuant to § 7 (2) and (3) GCP-V were summarized in the **Other objections** category. The most common were:

Recommendation (or demand, in some cases) to take out accident en-route insuranceDemand to ensure patient data protection (i.e. pseudonymization and anonymization, respectively) when collecting personal related data (e.g. no full date of birth or double coding for genetic testing)Request for clarifications and recommendations related to application documents pursuant to GCP-V § 7 (2) and (3)

Discussion
==========

The obtained results from 2 comparable surveys within a time period of 4 years are based on 21% of all applications for authorization of commercial and non-commercial phase I--IV clinical trials submitted to the regulatory authorities (BfArM and PEI) in 2007 \[[@R4]\], \[[@R5]\] and 2011 \[[@R3]\], \[[@R4]\], respectively and therefore might be deemed to be representative. It cannot be ruled out that the small differences observed may be partly due to structural differences between the time points. A full statistical analysis could not be applied to all parameters due to confidentiality of some data. The results may be viewed from different perspectives, i.e. what do the data reveal for the process of performing clinical studies in Germany, what is the consequence and learning for the sponsors and ECs for clinical trials conducted in Germany and last but not least what is the impact on the rights and well-being of patients in clinical trials.

Patients in clinical research -- what has changed?
--------------------------------------------------

For patients it's important to understand the research question and the benefits and risks of their study participation. This includes understanding the patient information, the content of the informed consent, and data protection aspects. With respect to the documents most relevant for patients, ECs are focusing on patient information and consent form. More than 50% of all objections, slightly increased from 53% (2007) to 57% (2011), are related to this topic. Also, objections related to data protection seem to play an increasingly important role. By critically reviewing study applications with respect to protecting patients, ECs are ensuring that patient rights, well-being and data privacy are addressed appropriately. From the surveys it seems that a trustful cooperation on a professional level between sponsors and ECs has developed over the years to safeguard patients and to allow for innovative research in unmet medical needs.

The clinical research environment
---------------------------------

The more reliable and standardized the EC procedures the better Germany's position as an attractive research location. Thus, the vfa is interested in insights how the EC process is perceived by companies and interested in how to learn and improve.

The amount of studies as well as the focus of indications has changed within 4 years. In comparison to 2007, a lower amount of applications (n=251 in 2011 vs. n=288 in 2007) was submitted to ECs. This is in line with data from both federal regulatory authorities in Germany BfArM and PEI \[[@R4]\], \[[@R5]\]. The amount of objections increased from 1,299 (2007) to 1,574 (2011), resulting in an average of 4.5 (2007) vs. 6.3 (2011) objections per application.

One reason for the increase in objections could be due to the fact that more complex studies, such as in i.e. oncology may require more intense review and a trend to more scientific input was observed in addition. Related to the trial protocol content, the focus of objections moved from more formal requests (e.g. to explain the method of contraception, to add the publication policy, SAE report address and monitoring details) to enquiries challenging the scientific rationale, the sample size and/or the primary endpoint. The increase in objections may also be due to intensified evaluation of patient related documents like patient information and consent documents as well as advertisement for patient recruitment.

Performance of ECs
------------------

In 2007 about 25% of 40 ECs reviewed 54% of applications while in the recent survey 18.6% of 43 ECs reviewed 49% of applications. Together with the observation that 40% of the 43 ECs in this survey assess roughly 75% of all applications, this could be seen as a trend towards concentration to specific ECs. This may also reflect a shift to more complex studies and certain indications. More scientifically challenging studies with innovative drugs in unmet medical needs may have to be conducted in specialized clinics and university hospitals. Thus, specific ECs allocated to these centers may get more applications consequently. This is also shown in an increase of applications submitted to ECs at university hospitals by almost 7% in 2011.

Similar to the previous survey the timelines for review (formal & content) were almost always kept, indicating reliability of EC processes and adherence to stipulated timeframes.

Sponsor -- EC Interaction
-------------------------

From the surveys, it seems that a shared understanding between sponsors and ECs has developed over the years. With respect to the frequency of formal and content related objections almost the same pattern was found in 2007 and 2011. However, the frequency of objections related to patient information and consent form, trial protocol, and § 7 increased considerably while objections to site and investigator quality dropped. The later observation could be attributed to some lessons learnt by sponsors and investigators while ECs harmonized their requirements on documents to support the qualification of site and study personnel.

Areas for improvement
---------------------

As observed in 2007, substantial heterogeneity in terms of requirements and evaluations, in particular with respect to patient information and consent document as well as application documents pursuant to GCP-V § 7 (2) and (3) still exists in 2011.

From the applicants' point of view, these requirements seem to be partly subjective in many cases rather than based on definite legal specifications. Also similar to 2007 about one quarter of objections lack legal basis or the requested data were already included in the submitted document package. However, constructive solutions were found in most cases of dissent between applicant and EC which enable both the implementation and justified non-implementation of actions on the objections in question.

Conclusions
===========

The present survey on clinical trial review procedures by ECs based on the experiences of the pharmaceutical companies represented in the vfa confirms both the distribution pattern and the type of formal and content related objections from the first survey. In line with current trends in the industry, more complex studies for unmet medical needs are conducted.

The majority of findings with respect to quantity, quality and main focus of objections reported in the first survey in 2008 were also found in 2012, indicating a shared understanding of applicable measures and criteria by sponsors and ECs on how to ensure patient rights and well-being, data integrity, and high quality documentation in clinical trials.

Although high level of expertise is seen in objections, high variance among ECs is notable. While patient information and consent form related objections remain number one priority, a wide variety of objections is noticed, depending on the individual EC. To further improve the dialogue between sponsors and ECs an increased alignment among ECs would be beneficial.

Notes
=====

Data
----

The underlying data are available upon request from the first author.
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